OrthoPediatrics (KIDS)
Builds pediatric orthopedic implants, scoliosis systems, and bracing services.
Something off on this page? Send us feedback.
Sells child-specific orthopedic implants, instruments, braces, and clinical O&P services across trauma/deformity correction, scoliosis, and smaller sports medicine/other procedures. The business reports one segment, serves mostly U.S. demand, and reaches international markets through a pediatric-focused product and education channel.
Designs and sells pediatric orthopedic implants, instruments, braces, and clinical O&P services for children with orthopedic conditions. The portfolio is grouped around trauma and deformity correction, scoliosis, and smaller sports medicine/other procedure lines, with one operating and reportable segment.
Recent additions widened the same pediatric focus: ApiFix brought non-fusion scoliosis technology, MD Orthopaedics added Mitchell Ponseti clubfoot bracing, Pega Medical added Fassier-Duval trauma/deformity systems, and Boston O&P added specialty bracing and clinics.
Demand is concentrated in the U.S., with distribution also reaching more than 70 countries outside the U.S. The model depends on pediatric surgeon adoption, clinical education, specialized field coverage, regulated device quality, and integration of acquired bracing and clinic assets.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 20, 2026 | BTIG | Reiterate | Rating: —Target: $23 | Target: $29 |
| Aug 5, 2026 | Truist Financial | Target | Target: $17 | Target: $22 |
| Aug 5, 2026 | Piper Sandler | Reiterate | Rating: —Target: $22 | Target: $25 |
| May 1, 2026 | Truist Financial | Target | Target: $18 | Target: $17 |
| Apr 24, 2026 | Canaccord Genuity | Target | Target: $24 | Target: $25 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $45.9M · Total debt $91.6M · Total assets $511.4M · Shareholders' equity $343.6M
- Revenue
- $70.5M
- Operating income
- −$4.1M
- Net income
- −$7.2M
No dividends on record.
| Institutions | 63.96% | 16.70M shares | |
|---|---|---|---|
| 121 holders · as of Jun 30, 2026 | |||
| Insiders | 30.09% | 7.86M shares | |
| 15 holders · as of Sep 10, 2026 | |||
| Other | 5.95% | 1.55M shares | |
| remainder | |||
26.11M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
David R. PelizzonInsiderdirector, 10 percent owner | 23.92% | 6.25M | filed Sep 10, 2026 |
Brown Advisory IncInstitution | 6.43% | 1.68M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 4.87% | 1.27M | as of Jun 30, 2026 |
Braidwell LPInstitution | 4.21% | 1.10M | as of Jun 30, 2026 |
Granahan Investment Management, LLCInstitution | 4.16% | 1.09M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 10, 2026 | Squadron Capital LLC | 10 percent owner | −302,369 | $21.01 |
| Sep 10, 2026 | Jennifer N. Pritzker | 10 percent owner | −302,369 | $21.01 |
| Sep 10, 2026 | David R. Pelizzon | director, 10 percent owner: | −302,369 | $21.01 |
| Sep 2, 2026 | Jennifer N. Pritzker | 10 percent owner | −22,500 | $23.35 |
| Sep 2, 2026 | Squadron Capital LLC | 10 percent owner | −22,500 | $23.35 |
- Johnson & Johnson
Broad DePuy Synthes overlap in trauma, spine, and sports
- Stryker
Major trauma, extremities, spine, and surgical-tech incumbent
- Medtronic
Spine implants, navigation, robotics, and enabling-tech rival
- Smith & Nephew (ADR)
Trauma, extremities, and sports medicine overlap via NYSE ADR
- Orthofix Medical
Direct limb reconstruction, spine, biologics, and 7D navigation overlap
- Globus Medical
Spine, trauma, limb reconstruction, and navigation competitor
- Enovis
Bracing, recovery, sports medicine, and reconstructive overlap
- Zimmer Biomet
Broad orthopedic incumbent with trauma, extremities, and sports lines
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| OrthoPediatrics | $22.76 | −0.26% | $574.1M | — | — | 2.3 | +15.4% |
| Johnson & Johnson | $269.17 | −0.04% | $649.40B | 31.2 | 22.7 | 6.6 | +6.6% |
| Stryker | $275.09 | +0.01% | $105.11B | 28.4 | 17.2 | 4.1 | +9.4% |
| Medtronic | $90.88 | +0.12% | $117.44B | 22.6 | 15.1 | 3.1 | +13.7% |
| Smith & Nephew (ADR) | $27.49 | −0.02% | $11.63B | 19.0 | — | 1.8 | +4.6% |
| Orthofix Medical | $8.98 | −0.11% | $361.8M | — | — | 0.4 | +5.1% |
| Globus Medical | $75.19 | −0.03% | $10.02B | 19.1 | 14.7 | 3.2 | +5.9% |
| Enovis | $17.70 | −3.67% | $1.04B | — | 5.1 | 0.5 | +3.2% |
| Zimmer Biomet | $93.98 | −0.04% | $18.25B | 22.9 | 10.7 | 2.1 | +4.8% |
| Median | 22.8 | 14.9 | 2.6 | +5.5% |